Single-injection vaccines may overcome issues, such as high cost and poor patient compliance, of the multi-bolus regimes dominantly used in vaccination. However no such vaccine has been commercialized because time-controlled release, an unconventional release kinetics, is difficult to achieve. Here a new time-controlled release system using dynamic layer-by-layer (LBL) film as erodible coating was used to design single-injection vaccine. Unlike commonly used degradable polymers, dynamic LBL film disintegrates at a constant rate, thus allowing distinct pulsatile release of antigen at predetermined intervals. The release pattern of the single-injection vaccine mimics closely to that of ordinary multi-dose regimes. It elicits both humoral and cellular immune responses which are comparable to or even stronger than the corresponding multi-dose regime. In addition, it inhibits tumor growth more effectively. The new vaccine will not only improve patient compliance but also therapeutic outcome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bioadv.2022.212812 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vaccine Specifically for Immunocompromised Individuals against Superbugs.
ACS Nano
January 2025
College of Pharmaceutical Sciences, Zhejiang University, 866 Yuhangtang Road, Hangzhou, Zhejiang 310058, P. R. China.
Immunocompromised populations, including cancer patients, elderly individuals, and those with chronic diseases, are the primary targets of superbugs. Traditional vaccines are less effective due to insufficient or impaired immune cells. Inspired by the "vanguard" effect of neutrophils (NE) during natural infection, this project leverages the ability of NE to initiate the NETosis program to recruit monocytes and DC cells, designing vaccines that can rapidly recruit immune cells and enhance the immune response.
View Article and Find Full Text PDFPersonalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8CD69 T cells.
J Immunother Cancer
December 2024
The United Innovation of Mengchao Hepatobiliary Technology Key Laboratory of Fujian Province, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, P. R. China
Background: Liver metastasis is highly aggressive and immune tolerant, and lacks effective treatment strategies. This study aimed to develop a neoantigen hydrogel vaccine (NPT-gels) with high clinical feasibility and further investigate its efficacy and antitumor molecular mechanisms in combination with immune checkpoint inhibitors (ICIs) for the treatment of liver metastases.
Methods: The effects of liver metastasis on survival and intratumor T-cell subpopulation infiltration in patients with advanced tumors were investigated using the Surveillance, Epidemiology, and End Results Program (SEER) database and immunofluorescence staining, respectively.
Clinical efficacy and safety of a single administration of fluralaner injectable suspension (BRAVECTO injectable) vs. monthly administration of oral afoxolaner (NexGard) in dogs for tick and flea control over one year under European field conditions.
Parasit Vectors
December 2024
MSD Animal Health Innovation GmbH, Schwabenheim, Germany.
Background: Year-round control of canine flea and tick infestations requires owner compliance with recommendations for regular treatments. Compliance failures can result in increased exposure of dogs to tick-borne pathogens and resurgence of flea populations. This study investigated the year-long efficacy of fluralaner 150 mg/ml injectable suspension (BRAVECTO injectable), developed to remove the need for multiple owner-administered, within-year treatments.
View Article and Find Full Text PDFA Phase 1b/2a Single Ascending Dose Study of a Half-life Extended RSV Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants.
J Infect Dis
November 2024
Merck & Co., Inc., Rahway, NJ, USA.
Article Synopsis
- Clesrovimab is a new monoclonal antibody designed to prevent respiratory syncytial virus (RSV) disease in infants, tested in a study with 183 healthy infants aged 2 weeks to 8 months.
- The study found that Clesrovimab was well tolerated, with the most common side effect being irritability, and it demonstrated a long half-life of 44.9 days, along with improved serum neutralizing antibodies over time.
- Infants who received Clesrovimab had lower rates of RSV-related illnesses compared to those given a placebo, indicating its potential effectiveness for further development in clinical trials.
Adjuvanted Modified Bacterial Antigens for Single-Dose Vaccines.
Int J Mol Sci
October 2024
GSK Vaccines Institute for Global Health (GVGH), 53100 Siena, Italy.
Alum is the most used vaccine adjuvant, due to its safety, low cost and adjuvanticity to various antigens. However, the mechanism of action of alum is complex and not yet fully understood, and the immune responses elicited can be weak and antigen-dependent. While several antigens rapidly desorb from alum upon exposure to serum, phosphorylated proteins remain tightly bound through a ligand-exchange reaction with surface hydroxyls on alum.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!